CEL-SCI Corporation (CVM) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

CEL-SCI Corporation (CVM) Healthcare & Pipeline Overview

CEL-SCI Corporation, a biotechnology firm, pioneers immunotherapy research, highlighted by its Multikine Phase III trial for head and neck cancer. Leveraging its LEAPS technology, the company targets a range of diseases, positioning it within the competitive biotech landscape focused on innovative immune-based therapies.

What Is the Investment Thesis for CVM?

CEL-SCI's investment thesis centers on the potential success of Multikine in its Phase III clinical trial for head and neck cancer. Positive trial results could lead to regulatory approval and subsequent commercialization, driving significant revenue growth. The company's LEAPS technology platform offers additional long-term value, with applications across various diseases. Key risks include clinical trial setbacks, regulatory hurdles, and the need for additional funding. The company's market capitalization is $0.03 billion as of 2026-05-10. Successful commercialization of even one of its product candidates could substantially increase shareholder value. The ongoing collaboration with the University of Georgia for LEAPS COVID-19 immunotherapy also presents a potential upside.

Based on FMP financials and quantitative analysis

CVM Key Highlights

Multikine is in Phase III clinical trials for head and neck cancer, representing a potential near-term catalyst.

• LEAPS technology platform offers broad applicability across multiple disease areas, including infectious diseases and autoimmune disorders.
• Collaboration with the University of Georgia's Center for Vaccines and Immunology for LEAPS COVID-19 immunotherapy.
• The company has a market capitalization of $10.0M as of 2026-05-10.
• No dividend yield, indicating a focus on reinvesting earnings into research and development.

Who Are CVM's Competitors?

CVM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CVM's Key Strengths?

Proprietary LEAPS technology platform.

• Multikine in Phase III clinical trials.
• Collaboration with the University of Georgia.
• Focus on immunotherapy for cancer and infectious diseases.

What Are CVM's Weaknesses?

Limited financial resources.

• Dependence on the success of Multikine.
• High risk associated with clinical trials.
• No currently marketed products.

What Could Drive CVM Stock Higher?

CVM catalyst: Announcement of results from the Phase III clinical trial of Multikine for head and neck cancer.

• Potential regulatory submissions for Multikine based on trial outcomes.
• Continued development of the LEAPS technology platform.
• Progress in the collaboration with the University of Georgia for LEAPS COVID-19 immunotherapy.

What Are the Key Risks for CVM?

Financial-distress signal — its Altman Z-Score of -39.12 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of the Phase III clinical trial of Multikine.
• Regulatory delays or rejection of Multikine.
• Competition from other immunotherapy companies.
• Need for additional funding to support research and development.

What Are the Growth Opportunities for CVM?

• Successful completion of the Multikine Phase III trial and subsequent regulatory approval represents a significant growth opportunity. The head and neck cancer market is substantial, and Multikine could capture a significant share if proven effective. The timeline for potential FDA approval is dependent on the trial results and regulatory review process. A successful launch would establish CEL-SCI as a key player in the cancer immunotherapy space.
• The LEAPS technology platform offers a broad range of potential applications across various diseases, including infectious diseases, autoimmune disorders, and other forms of cancer. Further development and commercialization of LEAPS-based therapies could drive long-term growth. The company's pre-clinical programs, such as CEL-2000 and CEL-4000 for rheumatoid arthritis, represent potential future revenue streams. The timeline for these programs is dependent on research and development progress.
• The collaboration with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy presents a growth opportunity in the infectious disease space. While the urgency of COVID-19 has diminished, there remains a need for effective immunotherapies to combat the virus and its variants. Successful development and commercialization of LEAPS COVID-19 could generate revenue and enhance CEL-SCI's reputation.
• Expansion of the company's pipeline through strategic partnerships and acquisitions could drive future growth. CEL-SCI could seek to acquire or license promising technologies or product candidates that complement its existing portfolio. This would diversify the company's risk and increase its long-term growth potential. The timeline for such initiatives is dependent on market opportunities and available funding.
• Geographic expansion into new markets could drive revenue growth. CEL-SCI could seek to commercialize its products in international markets, particularly in regions with high unmet needs for cancer and infectious disease treatments. This would require establishing partnerships with local distributors and navigating regulatory requirements in each market. The timeline for geographic expansion is dependent on regulatory approvals and market access strategies.

What Are CVM's Competitive Advantages?

• Proprietary LEAPS technology platform.
• Multikine Phase III clinical trial (potential first-mover advantage).
• Collaboration with the University of Georgia.
• Patents protecting its technologies and product candidates.

What Does CVM Do?

CEL-SCI Corporation, founded in 1983 and headquartered in Vienna, Virginia, is a biotechnology company dedicated to the research and development of innovative immunotherapies. The company's primary focus is on developing treatments for cancer and infectious diseases, leveraging its proprietary technology platforms to stimulate the body's immune system to fight these conditions. CEL-SCI's lead investigational immunotherapy, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. This pivotal trial represents a significant milestone for the company and the potential to address a critical unmet need in cancer treatment. Beyond Multikine, CEL-SCI is also developing the Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process. LEAPS aims to stimulate the human immune system to combat bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various forms of cancer. The company's pipeline includes LEAPS-H1N1-DC, CEL-2000, and CEL-4000, product candidates targeting rheumatoid arthritis, and LEAPS COV-19, a product candidate designed to treat the COVID-19 coronavirus. CEL-SCI collaborates with the University of Georgia's Center for Vaccines and Immunology to advance the development of LEAPS COVID-19 immunotherapy, showcasing its commitment to partnerships and innovation.

What Products and Services Does CVM Offer?

• Researches and develops immunotherapies for cancer and infectious diseases.
• Conducts Phase III clinical trials for Multikine in the treatment of head and neck cancer.
• Develops the Ligand Epitope Antigen Presentation System (LEAPS) technology.
• Creates product candidates for rheumatoid arthritis (CEL-2000 and CEL-4000).
• Develops LEAPS COV-19 as a product candidate to treat COVID-19.
• Collaborates with the University of Georgia to develop LEAPS COVID-19 immunotherapy.

How Does CVM Make Money?

• Focuses on research and development of immunotherapies.
• Generates revenue through potential future sales of approved therapies.
• Seeks partnerships and collaborations to advance development programs.
• Relies on funding through grants, investments, and potential future product sales.

What Industry Does CVM Operate In?

CEL-SCI operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential. The immunotherapy market is experiencing substantial growth, driven by advancements in understanding the human immune system and its role in fighting diseases. Companies like CEL-SCI are at the forefront of developing innovative therapies that harness the power of the immune system to treat cancer and infectious diseases. The industry is highly competitive, with both large pharmaceutical companies and smaller biotech firms vying for market share. Success depends on factors such as clinical trial outcomes, regulatory approvals, and commercialization strategies.

Who Are CVM's Key Customers?

• Patients with head and neck cancer (potential Multikine users).
• Patients with rheumatoid arthritis (potential CEL-2000 and CEL-4000 users).
• Patients with COVID-19 (potential LEAPS COV-19 users).
• Healthcare providers and institutions.

Company Profile

CEL-SCI Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vienna, US. The company is led by CEO Geert R. Kersten. CVM has traded publicly since 1983.

CEL-SCI Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -39.12 places it in the distress zone, a signal of elevated financial risk.

Return on assets is -70.3%, showing how much profit it generates from its asset base. CVM trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.60 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

CVM Valuation & Market Position

With a $10.0M market cap, CEL-SCI Corporation sits in the micro-cap segment of the market. Relative to its peer group, CVM's quantitative score of 25/100 is below the peer average of 79/100.

Wall Street analysts project CEL-SCI Corporation revenue of about $4.7M for fiscal 2026, with EPS near $-3.07.

CVM Financials

CVM Latest News

CVM Analyst Consensus

CVM MoonshotScore

CVM Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources